Form 13-F position report

PTC THERAPEUTICS INC

Reported by LOOMIS SAYLES & CO L P

PTCT CUSIP 69366J200 Manager CIK 0000312348

Reported 0 shares, down 1,061,398 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2023
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 17 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 61188000
2022-03-31 61441000
2022-06-30 65571000
2022-09-30 81269000
2022-12-31 46807000
2023-03-31 59634000
2023-06-30 43167000
2023-09-30 0
2026-03-31 33629173
2026-06-30 48156807
2026-09-30 41431928

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for PTC THERAPEUTICS INC held by LOOMIS SAYLES & CO L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 639,579 +49,205 (8.3%) 0.05% $41,431,928 2026-11-12
Q2 2026 Added 590,374 +96,771 (19.6%) 0.06% $48,156,807 2026-08-14
Q1 2026 New 493,603 +493,603 (0.0%) 0.05% $33,629,173 2026-05-14
Q3 2023 Reduced 0 -1,061,398 (-100.0%) 0 $0 2023-11-09
Q2 2023 Reduced 1,061,398 -169,684 (-13.8%) 0.07% $43,167,000 2023-08-11
Q1 2023 Added 1,231,082 +4,817 (0.4%) 0.1% $59,634,000 2023-05-11
Q4 2022 Reduced 1,226,265 -392,629 (-24.3%) 0.09% $46,807,000 2023-02-10
Q3 2022 Reduced 1,618,894 -17,941 (-1.1%) 0.16% $81,269,000 2022-11-14
Q2 2022 Reduced 1,636,835 -9,949 (-0.6%) 0.12% $65,571,000 2022-08-05
Q1 2022 Added 1,646,784 +110,561 (7.2%) 0.08% $61,441,000 2022-05-13
Q4 2021 Added 1,536,223 +247,968 (19.2%) 0.07% $61,188,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

227 managers reported PTC THERAPEUTICS INC for Q3 2023.

Managers reporting PTC THERAPEUTICS INC in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WELLINGTON MANAGEMENT GROUP LLP Added 9,436,188 +2,649,824 0.04% $211,464,973 41 qtrs
FMR LLC Reduced 8,465,384 -1,787,740 0.02% $189,709,255 41 qtrs
VANGUARD GROUP INC Added 7,945,489 +393,012 < 0.01% $178,058,408 41 qtrs
RTW INVESTMENTS LP Unchanged 7,235,196 0 3.42% $162,140,742 28 qtrs
BlackRock Inc Added 6,934,449 +68,106 < 0.01% $155,401,002 41 qtrs
ARMISTICE CAPITAL LLC Added 6,150,000 +2,914,000 2.11% $137,821,500 20 qtrs
Camber Capital Management LP Added 3,400,000 +900,000 2.51% $76,194,000 9 qtrs
STATE STREET CORPORATION Reduced 3,168,860 -1,624 < 0.01% $71,014,153 41 qtrs
JANUS HENDERSON GROUP PLC Reduced 3,072,320 -524,430 0.05% $68,847,799 19 qtrs
FRANKLIN RESOURCES INC Reduced 2,057,233 -1,254,671 0.02% $46,102,599 21 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 09, 2023
Filing type
13F-HR
Position type
COMMON

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.